Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Favorable Nonclinical Safety Profile of RSVpreF Bivalent Vaccine in Rats and Rabbits.
Vaccines (Basel)
December 2024
Drug Safety Research and Development, Pfizer Research & Development, Pearl River, NY 10965, USA.
: Respiratory syncytial virus (RSV) infections usually cause mild, cold-like symptoms in most people, but are a leading infectious disease causing infant death and hospitalization and can result in increased morbidity and mortality in older adults and at-risk individuals. Pfizer has developed Abrysvo, an unadjuvanted bivalent recombinant protein subunit vaccine containing prefusion-stabilized fusion (F) proteins representing RSV A and RSV B subgroups (RSVpreF). It is the only RSV vaccine approved for both maternal immunization to protect infants and active immunization of older adults (≥60 years) and 18-59-year-old individuals with high-risk conditions for prevention of RSV disease.
View Article and Find Full Text PDFRSV immunization uptake among infants and pregnant persons - Wisconsin, October 1, 2023-March 31, 2024.
Vaccine
January 2025
Wisconsin Division of Public Health, 1 West Wilson St., Madison, WI, United States.
Respiratory syncytial virus (RSV) is the leading cause of hospitalizations among infants in the United States. New strategies to prevent RSV among infants and high-risk young children include the maternal RSVpreF vaccine (Abrysvo, Pfizer Inc.) and nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting monoclonal antibody.
View Article and Find Full Text PDFProvider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment.
Obstet Gynecol Surv
October 2024
OBGYN Associate Professor, University of California San Francisco, Fresno, CA.
Importance: In 2023, the Food and Drug Administration approved 2 new products to reduce the risk of lower respiratory infections caused by respiratory syncytial virus (RSV) in infants: Beyfortus (nirsevimab; AstraZeneca/Sanofi), a single-dose monoclonal antibody for infant administration, and Abrysvo (bivalent RSVpreF vaccine; Pfizer), a single-dose maternal vaccination.
Objectives: We aimed to synthesize data from the literature and the leading professional organizations to provide guidance on RSV and strategies to reduce the risk of infant infection. This information will assist prenatal care clinicians in counseling their patients regarding the choice between maternal vaccination and the infant monoclonal antibody.
RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory Syncytial Virus Infection.
Am Fam Physician
June 2024
Prisma Health/University of South Carolina School of Medicine-Columbia, Columbia, South Carolina.
Vaccines for Respiratory Syncytial Virus Prevention in Older Adults.
Ann Pharmacother
December 2024
Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Objective: This review evaluates the efficacy and safety of novel respiratory syncytial virus (RSV) vaccines approved for adults aged 60 years and older.
Data Sources: A literature search through February 27, 2024 was conducted using search terms, such as RSV, viral respiratory illness, vaccine, RSVpreF, RSVpreF3, Prefusion F, Abrysvo, and Arexvy.
Study Selection And Data Extraction: Data from primary literature and vaccine prescribing information were reviewed, encompassing evaluations of clinical pharmacology, efficacy, safety, adverse events, warnings, and precautions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!